Related Experiment Videos
Bardoxolone brings Nrf2-based therapies to light
Antioxidants & Redox Signaling
|December 12, 2012
Summary
Bardoxolone
Area of Science:
- Pharmacology
- Nephrology
- Molecular Biology
Background:
- The nuclear factor erythroid-derived-2-like 2 (Nrf2) pathway is a key regulator of cellular defense against oxidative stress.
- Targeting Nrf2 shows promise for treating chronic kidney disease (CKD).
- Bardoxolone, a Nrf2 activator, demonstrated potential but faced clinical trial failure.
Discussion:
- The failure of bardoxolone in Phase III trials necessitates an examination of its clinical development.
- Potential reasons for bardoxolone's withdrawal include the chosen clinical indication and lack of target specificity.
- Investigating whether a different indication or improved specificity could have ensured safety and efficacy is crucial.
Key Insights:
- The clinical development of bardoxolone highlights challenges in Nrf2-based therapy for CKD.
- Specificity of Nrf2 activators is critical for mitigating safety concerns.
- Identifying the optimal clinical indication is paramount for therapeutic success.
Outlook:
- Despite setbacks, the Nrf2 pathway remains a promising drug target for various diseases.
- Future Nrf2-based therapies require careful selection of indications and enhanced molecular specificity.
- Successful Nrf2 modulation could offer novel therapeutic strategies for kidney disease and beyond.
Related Concept Videos
NF-κB-dependent Signaling Pathway
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Transducer Mechanism: Nuclear Receptors
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
NF-kB-dependent Signaling Pathway
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...